Zdravilo molnupiravir in predpisovanje v ambulantah primarne ravni

Vsebino predavanja si lahko ogledate tudi v spodnji prezentaciji.

&nbsp;
<ol>
<li>Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Pharmacol Res Perspect. 2022.Molnupiravir: A new candidate for COVID-19 treatment. Feb;10(1):e00909. doi: 10.1002/prp2.90</li>
<li>Fischer W, Eron JJ, Holman W,  et al. <a href="https://doi.org/10.1101/2021.06.17.21258639">Molnupiravir, an Oral Antiviral Treatment for COVID-19</a>. medRxiv. 2021 Jun 17:2021.06.17.21258639.</li>
<li>ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT04575597">Efficacy and safety of molnupiravir (MK-4482)  in non-hospitalized adult participants with covid-19(MK-4482-002)</a>. 2020.</li>
<li>Escobar PA, et al. Genotoxicity of MOV in vitro and in vivo. Abstract. EMGS, 2021</li>
<li>Troth S, Butterton J, DeAnda CS et al, Letter to the Editor in Response to Zhou et al, J Infect Dis. 2021 Oct 15; 224(8): 1442–1443.</li>
<li>Zhou S, Hill CS, Sarkar S, et al. . β-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis 2021;224:415–9.</li>
<li><a href="https://www.nature.com/articles/d41573-021-00202-8">Cully M. A tale of two antiviral targets — and the COVID-19 drugs that bind them</a>.</li>
<li style="font-weight: 400;" aria-level="1">MOVe-OUT Phase 3 Study: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116044?query=featured_home">Jayk Bernal A et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients</a>. N Engl J Med. 2021 Dec 16.</li>
<li style="font-weight: 400;" aria-level="1">MOVe-OUT Phase 2 Study: Caraco Y et al. <a href="https://evidence.nejm.org/doi/10.1056/EVIDoa2100043">Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults</a>. NEJM Evidence 2021. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults (nejm.org) </li>
<li style="font-weight: 400;" aria-level="1">MOVe-IN Phase 2 Study: Arribas JR et al. <a href="https://evidence.nejm.org/doi/10.1056/EVIDoa2100044">Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19</a>. NEJM Evidence 2021. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19 (nejm.org) </li>
<li style="font-weight: 400;" aria-level="1"><a href="https://www.covid19-druginteractions.org/checker">https://www.covid19-druginteractions.org/checker</a></li>
<li style="font-weight: 400;" aria-level="1"><a href="https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-conditions-use-conditions_en.pdf">https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-conditions-use-conditions_en.pdf</a></li>
<li style="font-weight: 400;" aria-level="1"><a href="https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf">https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf</a></li>
<li style="font-weight: 400;" aria-level="1"><a href="https://www.fda.gov/media/155053/download">https://www.fda.gov/media/155053/download</a></li>
<li style="font-weight: 400;" aria-level="1">Vangeel L , Chiu W , De Jonghe S., et al.  <a href="https://doi.org/10.1016/j.antiviral.2022.105252">Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern</a>. Antiviral Res; 2022 Jan 24;198:105252.</li>
</ol>

Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Zdravilo molnupiravir in predpisovanje v ambulantah primarne ravni

Reference

NOVO: Pregledovalnik interakcij zdravil